1. Lucentis is the first FDA-approved treatment for diabetic retinopathy patients with or without diabetic macular edema.
2. Tecentriq can now be used to treat patients with advanced bladder cancer who are not eligible for standard chemotherapy.
3. Cardea Solo is a wearable electrocardiogram sensor used to diagnose heart arrhythmias.
4. GammaCore is a handheld device used to treat cluster headaches.
More articles on supply chain:
Global pharmerging market to reach $1.4B by 2025
Price hikes likely added $8.7B to pharma’s net income for 2016, report finds
ASCO: Strategies to control drug costs hinder cancer patient care
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
